S1914

SWOG/NRG Joint Study: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Principal Investigator

Charles B. Simone II, MD

Status

Disease Site

Lung [LU] Non-small Cell Lung Cancer

Phase

III

Developmental Therapeutics

No

Primary Objective

To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.

NOTE:

This is a joint SWOG & NRG Oncology FDA registration-intent trial.  NRG Oncology institutions can credit NRG for their case accrual.  

SWOG Study Chair:  Megan E. Daly, M.D.

Patient Population

Patients must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0).  Patients may have T3 disease with the exclusion of multifocal tumors and pericardial involvement. 

Target Accrual

480